Drug intelligence / Profile preview

QL2108

Development stage: Phase 3
Lead developer: Qilu Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

QL2108 is a biosimilar to Dupixent® (dupilumab) being developed by Qilu Pharmaceutical for the treatment of atopic dermatitis. It is administered via subcutaneous injection and is currently undergoing clinical trials to evaluate its efficacy and safety compared to Dupixent® in adult patients with moderate to severe atopic dermatitis.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on QL2108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL2108.

Explore the full profile